All Stories

  1. An algorithm for the diagnosis of beta‐lactam allergy, 2024 update
  2. Diagnosis, Pathogenesis and Treatment of Chronic Spontaneous Urticaria
  3. An algorithm for the diagnosis, pathogenesis and treatment of chronic spontaneous urticaria, 2024 update
  4. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
  5. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial
  6. Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and Autoallergy
  7. Unveiling chronic spontaneous urticaria pathophysiology through systems biology
  8. Medical algorithm: Diagnosis and management of histaminergic angioedema
  9. Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria
  10. Classification and Treatment of Angioedema without Wheals: A Spanish Delphi Consensus
  11. Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccines
  12. Reliability of a novel electro‐medical device for wheal size measurement in allergy skin testing: An exploratory clinical trial
  13. Consensus on the Definition of Control and Remission in Chronic Urticaria
  14. Unraveling the Diagnosis of Kiwifruit Allergy: Usefulness of Current Diagnostic Tests
  15. Autoimmune chronic spontaneous urticaria
  16. Urticaria crónica espontánea : abordaje diagnóstico y terapéutico
  17. Validation of a commercial allergen microarray platform for specific immunoglobulin E detection of respiratory and plant food allergens
  18. [Artículo traducido] Práctica clínica diaria en el manejo de la urticaria crónica en España: resultados del estudio UCREX
  19. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
  20. Validation of novel recipes for masking peanuts in double-blind, placebo-controlled food challenges
  21. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]
  22. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema
  23. ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases
  24. Role of nanostructures in allergy: Diagnostics, treatments and safety
  25. Approach to Occupational Contact Dermatitis in an Industrialized Region of Spain
  26. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
  27. A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience
  28. Identification and Characterization of IgE‐Reactive Proteins and a New Allergen (Cic a 1.01) from Chickpea (Cicer arietinum)
  29. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper
  30. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
  31. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria
  32. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study
  33. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
  34. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
  35. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)
  36. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
  37. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  38. Biologics in chronic urticaria
  39. Allergy rhinitis: similarities and differences between children and adults
  40. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  41. Improvement of the Elevated Tryptase Criterion to Discriminate IgE- From Non–IgE-Mediated Allergic Reactions
  42. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria
  43. Adjuvants for allergy immunotherapeutics
  44. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
  45. Angio-oedema without hives, IgE and omalizumab
  46. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  47. Allergy rhinitis: similarities and differences between children and adults
  48. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion
  49. Induction of tolerance to different types of fish through desensitization with hake
  50. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis
  51. Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements
  52. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study
  53. Pros and Cons of Clinical Basophil Testing (BAT)
  54. Basophil activation testing in diagnosis and monitoring of allergic disease – an overview
  55. Valoración de tutores clínicos y estudiantes de medicina respecto a las rotaciones en centros de atención primaria y hospitales
  56. Technical flaws in multiple-choice questions in the access exam to medical specialties (“examen MIR”) in Spain (2009–2013)
  57. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
  58. Comparable actions of omalizumab on mast cells and basophils
  59. The Incidence of Perioperative Sensitivity Reactions
  60. Validation of The Spanish Version of The Urticaria Activity Score (Uas) and Its Use Over One Week (Uas7)
  61. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease
  62. Immunological events in chronic spontaneous urticaria
  63. Profile of omalizumab in the treatment of chronic spontaneous urticaria
  64. The Incidence of Perioperative Hypersensitivity Reactions
  65. Are all new allergens in TRUE Test®essential for a baseline set?
  66. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema
  67. Management of urticaria: not too complicated, not too simple
  68. Identification and Characterization of a New Oil Body Fraction Peanut Allergen
  69. Satisfacción de los estudiantes ante una sesión de exploración cardiológica impartida por compañeros entrenados
  70. Management of angioedema without urticaria in the emergency department
  71. Nanoparticle based-immunotherapy against allergy
  72. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  73. Perioperative Reactions: Are They So Infrequent?
  74. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions
  75. Pomegranate (Punica granatum L.) Expresses Several nsLTP Isoforms Characterized by Different Immunoglobulin E-Binding Properties
  76. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain
  77. A Randomized Trial of Cardiopulmonary Resuscitation Training for Medical Students
  78. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice
  79. Bilastine for the treatment of urticaria
  80. Analysis of the Association Between Food Allergy and Sensitization to Ltp and Profilin
  81. The Absence of Oil Body Proteins in Allergenic Extract Might Be Involved in False-Negative Diagnosis of Some Peanut Allergic Patients
  82. Pru p 3 acts as a strong sensitizer for peanut allergy in Spain
  83. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria
  84. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  85. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
  86. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  87. Research needs in allergy: an EAACI position paper, in collaboration with EFA
  88. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  89. Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy?
  90. Pharmacokinetic evaluation of levocetirizine
  91. Omalizumab is effective in nonautoimmune urticaria
  92. Ara H 9 Is The Main Allergen In Peanut Allergic Patients In The Mediterranean Area Regardless The Symptom Severity
  93. Diagnostic Reliability Of The Component-based Allergen-microarray In Grass, Cypress And Olive Pollens Allergy
  94. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study
  95. Creating Biomimetic Polymeric Surfaces by Photochemical Attachment and Patterning of Dextran
  96. Serum total tryptase levels are increased in patients with active chronic urticaria
  97. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study
  98. Differences In The Immunologic Response To Peanut Allergen Depending Upon The Route, Lipid Content And Peanut Roasting In An Animal Model
  99. In vitro Diagnosis of Anaphylaxis
  100. Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine
  101. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  102. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer
  103. Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
  104. Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer
  105. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  106. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy)
  107. Molecular Diagnosis by Microarray Technology in Polysensitized Atopic Patients
  108. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  109. Chronic urticaria: What is new, where are we headed
  110. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  111. Progress and Challenges in the Understanding of Chronic Urticaria
  112. Progress and Challenges in the Understanding of Chronic Urticaria
  113. Usefulness Of Specific Ige Determination To Recombinant Grass Pollen Allergens (cap-feia) In Pollinic Patients
  114. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  115. Study of the Role of Basophils in Skin Biopsies of Urticaria
  116. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli
  117. Gantrez® AN nanoparticles do not alter allergenicity of Lollium extract
  118. Comments regarding 'Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells' by Asero et al. M. Ferrer
  119. Urticaria crónica: estudio etiológico prospectivo e importancia del síndrome autoinmune
  120. IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera
  121. Siberian hamster: a new indoor source of allergic sensitization and respiratory disease
  122. Secretion of Cytokines, Histamine and Leukotrienes in Chronic Urticaria
  123. Intracellular cytokine IL4 and INF-gamma production in lymphocytes from patients with chronic urticaria
  124. Amiodarone-induced angioedema
  125. Complement dependence of histamine release in chronic urticaria☆☆☆
  126. Importance of food allergy in atopic dermatitis
  127. In vitro antigen‐specific sulphidoleukotriene production in patients allergic to Dermatophagoides pteronyssinus
  128. Comparative studies of functional and binding assays for IgG anti-FcϵRIα (α-subunit) in chronic urticaria☆☆☆★★★
  129. Sulphidoleukotriene and Histamine Releasability in Atopic Patients
  130. 406 Sulphidoleukotriene releasability in pollinic patients
  131. Specific Immunotherapy Induces Changes in Spontaneous IgE Synthesis